Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Has stable schizophrenia or schizoaffective disorder~* Has demonstrated ability to tolerate aripiprazole~* Has been on a stable antipsychotic medication regimen without any changes for at least 2 months prior to screening~* Has a body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive~* Additional criteria may apply~Exclusion Criteria:~* Is pregnant, breastfeeding, or is planning to become pregnant during the study period~* Has received aripiprazole lauroxil or IM depot aripiprazole within 6 months, or other long-acting, injectable antipsychotic medication within 3 months~* Is a danger to himself/herself at screening or upon admission~* Has a history of or positive test result for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C~* Has a positive urine drug screen at screening or Day 1~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole Lauroxil - A (Type: EXPERIMENTAL): Intramuscular (IM) injection Dose and Dosing Sequence A
- Aripiprazole Lauroxil - B (Type: EXPERIMENTAL): Intramuscular (IM) injection Dose and Dosing Sequence B
- Aripiprazole Lauroxil - C (Type: EXPERIMENTAL): Intramuscular (IM) injection Dose and Dosing Sequence C
- Aripiprazole Lauroxil - D (Type: EXPERIMENTAL): Intramuscular (IM) injection Dose and Dosing Sequence D

Based on this trial design, predict the completion outcome and termination type (if applicable).